Categories
Aging & Disability Divergent News Healthcare & Wellness

FDA kicks back Acer’s rare disease drug, demands new test—shares in freefall | FierceBiotech

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol). Source: FDA kicks back Acer’s rare disease drug, demands new test—shares in freefall | FierceBiotech